abrdn Life Sciences Investors - Common Shares, $0.01 par value (HQL)

Historical Holders from Q3 2014 to Q3 2025

Symbol
HQL on NYSE
Type / Class
Equity / Common Shares, $0.01 par value
Shares outstanding
28,862,386
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
9,135,004
Holdings value
$141,447,637
% of all portfolios
0%
Number of holders
81
Number of buys
45
Number of sells
-25
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of abrdn Life Sciences Investors - Common Shares, $0.01 par value (HQL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Saba Capital Management, L.P. 7.88% -12% $39,778,486 -$5,462,057 2,274,356 -12% Saba Capital Management, L.P. 21 Nov 2025
FIRST TRUST PORTFOLIOS LP 6.33% $23,039,882 1,827,112 First Trust Portfolios L.P. 31 Mar 2025

Institutional Holders of abrdn Life Sciences Investors - Common Shares, $0.01 par value (HQL)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 9,135,004 $141,447,637 -$612,075 $15.51 81
2025 Q2 9,160,432 $117,354,763 +$3,718,136 $12.81 75
2025 Q1 8,871,741 $112,593,442 -$7,767,200 $12.69 82
2024 Q4 9,477,441 $124,355,615 -$6,077,782 $13.12 72
2024 Q3 9,873,051 $148,865,144 +$3,496,897 $15.08 74
2024 Q2 9,607,549 $136,221,681 +$7,416,967 $14.17 75
2024 Q1 9,097,810 $123,989,537 +$15,543,590 $13.63 79
2023 Q4 7,957,094 $107,172,259 +$20,629,421 $13.46 79
2023 Q3 6,434,689 $80,230,199 +$11,333,847 $12.47 79
2023 Q2 5,495,691 $74,402,090 +$3,747,676 $13.54 78
2023 Q1 5,218,628 $72,689,568 +$181,766 $13.93 78
2022 Q4 5,215,082 $74,160,302 +$13,461,137 $14.21 79
2022 Q3 4,273,316 $58,377,986 +$8,412,428 $13.66 59
2022 Q2 3,670,943 $52,261,963 +$42,180 $14.23 63
2022 Q1 3,659,571 $60,566,148 -$3,857,113 $16.54 62
2021 Q4 3,874,395 $74,397,923 -$4,344,897 $19.23 62
2021 Q3 4,078,867 $85,055,000 -$6,796,791 $20.8 60
2021 Q2 4,393,839 $94,224,459 -$7,765,396 $21.44 62
2021 Q1 4,759,098 $93,769,016 -$3,063,175 $19.71 59
2020 Q4 4,901,740 $96,913,930 +$4,277,094 $19.75 61
2020 Q3 4,667,693 $82,119,114 +$2,719,515 $17.58 56
2020 Q2 4,593,229 $82,470,887 +$2,418,762 $17.96 65
2020 Q1 4,348,971 $65,182,146 +$3,312,576 $14.98 64
2019 Q4 4,081,292 $71,163,712 +$10,150,880 $17.43 62
2019 Q3 3,306,970 $50,015,468 +$2,019,469 $15.1 56
2019 Q2 3,165,675 $53,305,158 -$107,682 $16.85 50
2019 Q1 3,197,807 $54,748,908 -$880,173 $17.13 51
2018 Q4 3,256,357 $49,207,495 +$630,267 $15.11 53
2018 Q3 3,162,453 $64,565,945 -$620,909 $20.42 53
2018 Q2 3,204,169 $60,229,278 +$400,395 $18.79 57
2018 Q1 3,180,291 $60,941,490 +$2,123,352 $19.21 54
2017 Q4 3,055,824 $60,046,863 +$2,780,074 $19.63 53
2017 Q3 2,690,191 $57,884,029 +$5,149,401 $21.48 50
2017 Q2 2,450,878 $51,124,000 -$30,093 $20.85 43
2017 Q1 2,461,431 $47,583,000 -$1,650,891 $19.39 39
2016 Q4 2,565,495 $43,758,000 +$3,771,229 $16.99 44
2016 Q3 2,171,425 $40,653,000 -$924,995 $18.73 41
2016 Q2 2,226,005 $38,335,000 -$3,729,087 $17.19 46
2016 Q1 2,417,731 $43,421,000 -$4,199,541 $17.94 42
2015 Q4 2,618,012 $61,825,000 +$3,683,007 $23.64 46
2015 Q3 2,464,547 $55,596,000 +$3,050,178 $22.51 42
2015 Q2 2,302,053 $64,980,792 +$5,330,725 $28.21 41
2015 Q1 2,111,627 $58,177,144 -$947,913 $27.57 39
2014 Q4 2,150,612 $53,523,700 +$51,463,341 $24.88 38
2014 Q3 2,881 $64,000 +$64,000 $22.15 2